SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

IRIDEX Announces First Quarter 2014 Conference Call and Release Date

MOUNTAIN VIEW, Calif., April 24, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2014 financial results after the market closes on Thursday, May 1, 2014.  In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, May 1, 2014 to discuss the results of the quarter and other business developments.

Interested parties may access the live conference call via telephone by dialing (877) 407-0784 (US) or (201) 689-8560 (International) and requesting the IRIDEX First Quarter 2014 Earnings Conference Call, or by visiting the Company's website at www.iridex.com.   A telephone replay will be available beginning on Thursday, May 1, 2014 through Thursday, May 8, 2014 by dialing (877) 870-5176 (US) or (858) 384-5517 (International) and entering Replay Pin # 13580951.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com.

SOURCE IRIDEX Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.